Oral tyrosine kinase inhibitor shows promising early results in AMD patients
The analysis comprised data from two studies: a 14-day phase 1 placebo-controlled study with 72 healthy subjects and a 28-day phase 2a open-label study with 15 patients who had subfoveal choroidal neovascularization secondary to AMD.
The AMD patients received oral pazopanib 15-mg tablets once daily for 28 days. Healthy subjects received single or repeated oral pazopanib 5-, 10-, 20- or 30-mg tablets or placebo once daily for 14 days.
Patients were examined at baseline and weekly during treatment.
Administration of a 15-mg dose for 28 days yielded a mean eight-letter gain in best corrected visual acuity, a reduction in central retinal thickness of 50.28 µm and a reduction in central retinal lesion thickness of 50.94 µm in nine AMD patients who did not undergo rescue therapy.
Six AMD patients received intravitreal injection of anti-VEGF agents; all six patients had the high-risk CFH Y402H CC genotype for AMD.
Mild to moderate ocular adverse events were reported by seven of 15 patients in the AMD group. The most common non-ocular adverse events were intermittent headache in two patients and upper respiratory tract infection in two patients.
Pazopanib was well tolerated in the healthy subjects and patients with AMD.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.